XORTX Therapeutics (XORTX Therapeutics) Dividends per Share : $0.00 (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Dividends per Share?

XORTX Therapeutics's dividends per share for the three months ended in Sep. 2023 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2023 was 0.00. As of today, XORTX Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

XORTX Therapeutics Dividends per Share Historical Data

The historical data trend for XORTX Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Dividends per Share Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Dividends per Share

Get a 7-Day Free Trial

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of XORTX Therapeutics's Dividends per Share

For the Biotechnology subindustry, XORTX Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Dividend Yield % falls into.

XORTX Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

XORTX Therapeutics (NAS:XRTX) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

XORTX Therapeutics's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	-0.668
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

XORTX Therapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.